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Mutations of mtDNA are an important cause of hu-
man disease, but few animal models exist. Because
mammalian mitochondria cannot be transfected,
the development of mice with pathogenic mtDNA
mutations has been challenging, and the main strat-
egy has therefore been to introduce mutations found
in cell lines into mouse embryos. Here, we describe a
phenotype-driven strategy that is based on detecting
clonal expansion of pathogenic mtDNA mutations in
colonic crypts of founder mice derived from hetero-
zygous mtDNA mutator mice. As proof of concept,
we report the generation of a mouse line transmitting
a heteroplasmic pathogenic mutation in the alanine
tRNA gene of mtDNA displaying typical characteris-
tics of classic mitochondrial disease. In summary,
we describe a straightforward and technically simple
strategy based on mouse breeding and histology to
generate animal models ofmtDNA-mutation disease,
which will be of great importance for studies of
disease pathophysiology and preclinical treatment
trials.
INTRODUCTION
The biogenesis of the oxidative phosphorylation system is criti-
cally dependent on mtDNA expression (Larsson et al., 1998).
Consequently, mutations of mtDNA are an important cause of
mitochondrial disease (Greaves et al., 2012; Keogh and Chin-
nery, 2015) and are suggested to participate in the aging process
(Larsson, 2010). The pathophysiology of mtDNA disease is
poorly understood, as emphasized by the observation that
different types of mutations affecting tRNA genes often cause
distinct clinical phenotypes (Tyynismaa and Suomalainen,
2009). Single large deletions of mtDNA typically remove one or2980 Cell Reports 16, 2980–2990, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY license (http://creativeseveral tRNA genes and lead to amultisystem disease in children
(Larsson et al., 1990; Ro¨tig et al., 1990) or chronic progressive
external ophthalmoplegia (CPEO) with additional neuromuscular
symptoms in adults (Moraes et al., 1989). The A8344G mutation
in the tRNALYS (mt-Tk) gene causes myoclonus epilepsy and
ragged-red fibers syndrome (MERRF) (Shoffner et al., 1990),
whereas the A3243G mutation in the tRNALEU(UUR) (mt-Tl1)
gene can cause a spectrum of clinical phenotypes, including
maternally inherited diabetes and deafness (MIDD) (Nesbitt
et al., 2013); mitochondrial myopathy, encephalopathy, lactic
acidosis, and stroke-like episodes syndrome (MELAS) (Goto
et al., 1990); or CPEO (Moraes et al., 1992). The genotype-
phenotype correlations exemplified above are not at all under-
stood and are particularly enigmatic if one considers that all
mutations affecting tRNA genes should have the common effect
of impairing mitochondrial translation (Larsson and Clayton,
1995). In vivo experimental approaches are clearly needed to
better understand the pathophysiology of different types of
mtDNA mutations. Unfortunately, robust procedures for trans-
fection of mammalian mitochondria have so far not been devel-
oped, and attempts to generate mouse models have therefore
been focused on introducing pre-existing mtDNA mutations
from cell lines or somatic tissues into mice. One important strat-
egy to generate such transmitochondrial mice has been to
perform fusion between female karyotype embryonic stem cells
(ESCs) and cytoplasmic fragments containing mitochondria with
pathogenic mtDNA mutations. The first pathogenic mutation
introduced into mice with this technique affected the lrRNA
gene and conferred resistance to chloramphenicol toxicity
(Levy et al., 1999; Marchington et al., 1999; Watanabe et al.,
1978). The techniquewas subsequently amended by introducing
a step to remove the endogenous mitochondria in the ESCs by
treatment with the toxin rhodamine 6G prior to the introduction
of exogenous mitochondria (Sligh et al., 2000). Although this
procedure improved the efficiency for introduction of mutant
mtDNA, animals carrying high levels of the lrRNA gene mtDNA
mutation died as embryos or as newborn pups shortly after birth.
Pathogenic mtDNA mutations have also been introduced intouthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Breeding Scheme to Generate Mouse Lines Transmitting
Pathogenic mtDNA Mutations
Females heterozygous for the PolgAMUT allele are used to generate germline-
transmissible mtDNA mutations and mated to wild-type males. Female
offspring, which are wild-type at the PolgA locus, are further bred to generate
female-derived lines, transmitting the mutated mtDNAs. After establishing
maternal lineages to at least the third generation, founder females are sacri-
ficed and their colonic crypts screened. Colonic crypts in founder mice were
screened for the presence of mitochondrial dysfunction (some blue crypts on
COX/SDH staining). Established mouse lines where the founder showed
normal mitochondrial activity (only brown crypts on COX/SDH staining) were
discontinued. To identify mtDNAmutations segregating with the mitochondrial
dysfunction, the complete mitochondrial genome is sequenced from crypts
deficient in mitochondrial function (blue crypts). Using this screening pro-
cedure, we identified three distinct lines harboring COX-deficient cells out of
the 12 lines. See also Figure S1.mice by fusion of enucleated cytoplasm to fertilized oocytes.
This method has successfully been used to introduce dupli-
cated/deleted mtDNA into mice (Inoue et al., 2000; Nakada
et al., 2004), whereas the ESC method has been used to intro-
duce mtDNA with mutations affecting protein-coding genes
(Fan et al., 2008) or tRNA genes (Shimizu et al., 2014, 2015).
Some of these transmitochondrial mice develop mitochondrial
disease phenotypes such as cardiomyopathy, muscle atrophy,
and anemia (Fan et al., 2008; Inoue et al., 2000; Nakada et al.,
2004; Shimizu et al., 2015; Sligh et al., 2000). Unfortunately, a
clear drawback of the cytoplasmic fusion strategy is that it is
very laborious and that the choice of mutations is limited to those
that already exist in cell lines or somatic tissues. Furthermore,
some of the introduced mutations cannot be propagated in
mice (Fan et al., 2008) because of strong purifying selection in
the maternal germline (Stewart and Larsson, 2014).The mtDNA mutator mice are homozygous for a knockin mu-
tation in the gene encoding the catalytic subunit of the mtDNA
polymerase (PolgAMUT/MUT) and express a proofreading-defi-
cient enzyme with much reduced 30–50 exonucleolytic activity
(Ross et al., 2013; Trifunovic et al., 2004). As a consequence,
the PolgAMUT/MUT mice have extensive somatic and germline
mutagenesis of mtDNA and will transmit mutated mtDNA
through the germline (Ross et al., 2013; Stewart et al., 2008).
Mouse lines derived by breeding PolgAMUT/MUT females have
been valuable tools to study purifying selection and have clari-
fied that mutations causing amino acid substitutions in respira-
tory chain subunits are strongly selected against in the maternal
germline (Stewart and Larsson, 2014; Stewart et al., 2008).
In contrast, tRNA gene mutations are better tolerated and
mainly undergo purifying selection during embryonic develop-
ment (Freyer et al., 2012). Unfortunately, the breeding of
PolgAMUT/MUT mice results in mouse lines that have many linked
mutations in the same mtDNA molecule, which makes it diffi-
cult to establish firm genotype-phenotype correlations. These
models are therefore of limited usewhen it comes to understand-
ing the enigmatic pathophysiological effects of single specific
mtDNA mutations.
To overcome these limitations, we describe here a technically
simple and straightforward screening approach to create mice
with pathogenic mtDNA mutations. In a first step, heterozygous
mtDNA-mutator (PolgA+/MUT) femalesarebred toestablishmouse
lines with a wild-type nuclear background that each carries a very
limitednumberofmtDNAmutations. In a secondstep, the founder
individual of each line is sacrificed after having established a
maternal mouse line and colonic crypts are analyzed by enzyme
histochemistry to detect mosaic cytochrome c oxidase (COX)
deficiency. In the third step, laser-capture dissection and mtDNA
sequencing are performed on single colonic crypts to identify the
pathogenic mtDNA mutation and establish its pathogenicity.
Finally, identified mouse lines, where the founder mouse harbors
a specificheteroplasmicpathogenicmtDNAmutation, arebredas
maternal lines and extensively characterized. As a proof of princi-
ple,wedescribe here thecreationof amousemodel formitochon-
drial disease caused by a heteroplasmic C5024T mutation in the
tRNAALA (mt-Ta) gene of mtDNA, which recapitulates important
aspects of human mitochondrial disease.
RESULTS
Breeding of Mouse Lines to Isolate Single Pathogenic
mtDNA Mutations
The PolgAMUT/MUT genotype causes an approximately equal mu-
tation load in both the germline and somatic tissues (Ross et al.,
2013; Stewart et al., 2008), and we therefore estimated that the
breeding of PolgA+/MUT mice, which have a much lower somatic
mtDNA mutation load of 2 3 104 mutations/bp (Ross et al.,
2013), would induce approximately three mutations per trans-
mitted mtDNA molecule. We established a breeding strategy to
generate female lineages (n = 12 lineages; Figure 1) by first
crossing PolgA+/MUT males to wild-type C57BL/6N females to
obtain PolgA+/MUT females with reintroduced wild-type mtDNA.
In the subsequent cross (N1), the PolgA+/MUT females were
crossed with wild-type males to obtain females in the N2Cell Reports 16, 2980–2990, September 13, 2016 2981
generation that have a wild-type nuclear genome and contain
maternally inherited mtDNA mutations. These founder females
were further bred to establish maternal lineages to segregate
and clonally expand the maternally transmitted mtDNA muta-
tions. To validate that mtDNA mutations indeed had been intro-
duced, we performed completemtDNA sequencing from eight of
these lineages and observed the presence of heteroplasmic
mtDNA mutations in all of them from the N3 generation and on-
ward. The pattern of mtDNAmutations in these lineages showed
a strong bias against mutations changing the first and second
codon positions of protein coding genes, which is consistent
with strong purifying selection in the maternal germline (Fig-
ure S1; Stewart and Larsson, 2014; Stewart et al., 2008).
Detection of Clonally Expanded Pathogenic mtDNA
Mutations
The majority of the human mtDNA mutations affect tRNA genes,
and they will impair mitochondrial translation if present at high
enough levels. Mutations of mtDNA tend to undergo rapid segre-
gation in certain types of stem cells, and somatic mtDNA mu-
tations clonally expand to cause a mosaic respiratory chain
deficiency in colonic crypts in both humans (Greaves et al.,
2010; Taylor et al., 2003) and mice (Baines et al., 2014). We hy-
pothesized that this clonal expansion phenomenon would be a
powerful tool to identify pathogenic mtDNA mutations in our
mouse lines and establish their pathogenicity. To this end, we
analyzed the founder individual from each of the 12 mouse lines
and performed a combined COX and succinate dehydrogenase
(SDH) staining of colonic epithelium. With this technique, where
respiratory chain deficient cells appear blue and wild-type cells
brown, we identified respiratory-chain-deficient cells in the
founder mice of 3 of the 12 analyzed mouse lines. Next, we per-
formed laser-capture dissection of individual blue crypts and
sequenced mtDNA after PCR amplification. In one of the three
lines with COX-deficient colonic crypts (Figure 2A), we found
high levels of a heteroplasmic C5024T mutation in the tRNAALA
gene (Figure 2B). We developed an allele-quantifying pyrose-
quencing protocol to measure the levels of mutated mtDNA in
individual colonic crypts and found a significant correlation
between levels of the tRNAALA mutation and the occurrence of
respiratory chain deficiency (Figure 2C). The identified C5024T
mutation in mouse mtDNA disrupts the same base pair in the
acceptor stem of tRNAALA as the pathogenic G5650A mutation
found in human patients with a mitochondrial disease syndrome
(Figure 2D) (Finnila¨ et al., 2001; McFarland et al., 2008). The
human mutation introduces a second G-U wobble base pair in
the acceptor stem, while the mouse mutation generates a C-A
mismatch next to a U-U mismatch, which possibly could lead
to differences in tRNAALA stability despite the very similar struc-
tural location of the mutations in both species.
In addition to the tRNAALA mutation, we found a linked
C13715T mutation in themt-Nd6 gene, which changes an amino
acid (G-to-Dsubstitution at position 119) ofND6.Alignment of se-
quences from a number of rodents revealed that this site is very
poorly conserved and has a poor predicted pathogenicity score
(Figure S2A). Generally,mitochondrial tRNA (mt-tRNA)mutations
broadly affect mitochondrial translation, with many pathogenic
human mutations showing either simultaneous declines in com-2982 Cell Reports 16, 2980–2990, September 13, 2016plex I (CI) and complex IV (COX), or more rapid and severe de-
clines in CI relative to COX (Rocha et al., 2015). Examination of
the colonic crypts frommicewith high levels of the twomutations
using antibodies to theCI proteinNDUFB8 (Rocha et al., 2015) re-
vealed slightly more CI deficient crypts compared to the number
of crypts displaying COX deficiency (Figures S2C–S2E). Such a
pattern is consistent with mt-tRNA pathogenicity and did not
reveal a strongly enhanced CI defect as one would expect from
compounding mutations affecting CI. Mutations in the mito-
chondrially encoded CI subunits often lead to strong reductions
in the amount of CI found and the accumulation of partially
assembled CI (Bai and Attardi, 1998; Leman et al., 2015; Leshin-
sky-Silver et al., 2010; Lim et al., 2016; Lin et al., 2012; Ugalde
et al., 2007). Blue native PAGE was performed on mitochondria
from animals with high relative levels of the two mutations, and
we saw no decrease in the steady-state levels of CI or partially
assembledCI (Figure S2E). In-gel CI activity assays did not reveal
any biochemical deficiency (Figure S2F). These experiments
failed to reveal evidence of a pathogenic role for the mt-Nd6
mutation, and we thus conclude that this mouse line harbors a
single pathogenic mutation in the tRNAALA gene that causes
the observed respiratory chain deficiency.
The C5024T Mutation of the tRNAALA Gene Is Not
Neutrally Transmitted
When breeding mice with the tRNAALA mutation, we never
observed individuals harboring>80%of themutation in tail biopsy
specimens obtained at the age of 3 weeks (Figure 3A). Using the
Kimuramodel as a null hypothesis for neutral transmission, female
mice harboring low levels of the tRNAALAmutation (<51%; Figures
S3A and S3B) showed a transmission pattern fully consistent with
neutraldrift (Figure3B). Incontrast,micewithhigh levelsof themu-
tation (>55%) produced progeny with mtDNAmutation levels that
deviated from the neutral drift model (Figure 3B). The number of
pupswith highmutation levels wasmuch lower than the expected
frequency (Figure 3B) despite normal litter sizes (Figure S3C). We
have previously demonstrated that tRNA mutations undergo
selection in the post-fertilization embryo (Freyer et al., 2012). The
behavior of theC5024Tmutation implies that this selection occurs
in the absence of embryodeath, implicating a cellular or organellar
phenomenon as the source of this selection. Further work on the
mechanisms facilitating this selection is ongoing.
Reduced Body Mass and Cardiomyopathy in
Mutant Mice
Male mice harboring the tRNAALA mutation had reduced total
body mass, reduced lean mass and reduced fat content in
comparison with control males (Figure 4A), whereas females
were unaffected. The heartmass of both female andmalemutant
mice was increased, especially at high mutation levels (Fig-
ure 4B). A variety of tissues were analyzed with COX/SDH
enzyme histochemistry to detect respiratory-chain-deficient
cells. At the age of 20 weeks, COX deficiency was present in
the epithelial cells of colonic crypts, but not in other tissues. At
the age of 40 weeks and older, frequent COX deficiency was
observed in the smooth muscle surrounding the colon of mice
with >60% of the C5024T mutation (Figure 4C) as well as in oc-
casional cardiomyocytes (Figure S4). Laser-capture dissection
Figure 2. The tRNAALA C5024T Mutation Is
Identified as a Pathogenic mtDNA Mutation
(A) Representative COX/SDH staining of colonic
crypts from wild-type mouse (WT) and a mouse
that carries the tRNAALA C5024T mutation. Black
bar represents 100 mm. Crypts, which are brown,
have normal COX activity; those that are blue have
deficient COX activity.
(B) Electropherograms from mtDNA sequences
obtained from isolated colonic crypts from WT
mice and mice with the C5024T mutation shows
the correlation of relative level of C5024T mutation
andmitochondrial dysfunction in the colonic crypt.
The crypts that are positive for mitochondrial
function (COX+) show lower relative levels of the
C5024T mutation, and colonic crypts deficient in
mitochondrial function (COX) show higher rela-
tive levels of the C5024T mutation.
(C) Relative levels of the heteroplasmic C5024T
mutation in individually dissected colonic crypts
that are either COX positive or COX negative,
showing that high levels of the C5024T mutation
are present in the COX-negative colonic crypts.
Error bars indicate SD. ***p < 0.001; ****p < 0.0001
(Mann-Whitney U test).
(D) Clover-leaf representations of the tRNAALA
from humans (left) identifying the positions of
known pathogenic mutations and the location of
the C5024T mutation in the structure of tRNAALA
from mice (right).
See also Figure S2.of colonic smooth muscle cells showed a significant correlation
between the levels of the tRNAALA mutation and the occurrence
of COX deficiency (Figure 4D), again confirming the pathogenic
nature of the mutation.
Selection against High Mutation Levels in Proliferating
Tissues
The levels ofmutatedmtDNAwere similar in all analyzed tissues in
young animals (age 20 weeks) and reflected the levels in tail bi-Cell Reportsopsy specimens obtained atweaning (age
3 weeks) (Figure S5A). In contrast, the
mutation levels were decreased in the
highly proliferative colonic epithelium in
comparison with the surrounding smooth
muscle in oldermice (age>40weeks) (Fig-
ure 5A). Interestingly, a similar decrease of
mutation levels was seen in peripheral
blood of older mutant animals (Figure 5B).
Taken together, these findings show that
tissues with high proliferation can select
against high levels of the tRNAALA muta-
tion, whereas the levels remain constant
over time in lessproliferative tissues. Inter-
estingly, this type of selection manifested
as low mutation levels in peripheral blood
is also seen in some humanmtDNAmuta-
tion disease syndromes, such as CPEO
(Larsson and Clayton, 1995) and theA3243G MELAS mutation (Ciafaloni et al., 1991), whereas others
show a good correlation between mutation levels in peripheral
blood and skeletal muscle, such as the G8344A mutation, which
causes MERRF syndrome (Larsson et al., 1992).
The tRNAALA Mutation Impairs Mitochondrial
Translation
We analyzed the steady-state levels of different mtDNA-en-
coded RNAs and found a substantial decrease in the tRNAALA16, 2980–2990, September 13, 2016 2983
Figure 3. Transmission of the C5024T Mutation in Mice
(A) Comparison of the relative levels of the C5024T mutation in 1,105 offspring
to heteroplasmic mothers. The red line represents the observed maximum
level of the mutation.
(B) Four representative tests for neutral segregation of the C5024T mutation
using the Kimura distribution (Wonnapinij et al., 2008). Gray bars represent
the observed levels of the mutation compared to the expected neutral
distribution (orange line). Neutral segregation of the allele was observed
until the mother carries 59% of the C5024T mutation, and then the segre-
gation varies from the neutral prediction. All tests are represented in
Figure S3.
2984 Cell Reports 16, 2980–2990, September 13, 2016levels in the mutant animals (Figures 6A and S6). The other
analyzed tRNAs were present at either normal (tRNACYS,
tRNAASN, and tRNATRP) or slightly decreased levels (tRNAGLN;
Figure 6A). The levels of the srRNA and lrRNA were slightly
elevated, whereas the steady-state levels of the analyzed
mRNAs were unaltered (Co1) or slightly elevated (Nd2 and
Nd6; Figure 6A). We found low total levels of tRNAALA in animals
with high levels of mutated mtDNA (Figure 6B), consistent with
the idea that the mutation impairs the stability of tRNAALA. We
proceeded to investigate how the reduced levels of tRNAALA
affected mitochondrial translation (Figure 6C). The in organello
protein synthesis was decreased in tissues containing high
amounts of mutated mtDNA, showing that the tRNAALAmutation
indeed impairs mitochondrial translation (Figure 6C), and is
consistent with observations in human cell lines and tissues
that a certain threshold of mutated mtDNA is needed to impair
mitochondrial protein synthesis (Hayashi et al., 1991; Larsson
et al., 1992). The amino acid alanine is present in all mtDNA-en-
coded proteins and represents 5% of all amino acids in those
proteins, which explains the observed general decrease of mito-
chondrial translation in animals with high levels of the tRNAALA
mutation. In mitochondria with high levels of the tRNAALA muta-
tion and, consequently, markedly impaired overall mitochondrial
translation, we occasionally observed aberrant translation
products of low molecular weight (Figure 6C) consistent with
translational stalling or pre-mature termination of translation.
DISCUSSION
We describe here a technically simple phenotype-driven
approach to create mouse models for mitochondrial disease.
The protocol is based on breeding PolgA+/MUT females to derive
founder mice with a wild-type nuclear background followed by
identification of the pathogenic mtDNA mutations by analysis
of respiratory chain deficiency in colonic crypts. The founder
mice are only sacrificed for analysis of colon after the maternal
lines have been established from them. Pathogenic mtDNA mu-
tations frequently undergo clonal expansion in tissues with high
cell proliferation (Baines et al., 2014; Greaves et al., 2010; Taylor
et al., 2003) and we therefore utilized COX/SDH histochemistry
to detect mosaic COX deficiency in colonic epithelium. Laser-
capture dissection and mtDNA sequencing of single crypts
was then used to identify the mutation and its pathogenicity
was established by comparing the mutation levels in crypts
with normal or deficient COX activity. The unusually rapid clonal
expansion of mtDNA mutations in colonic crypts allows identifi-
cation of pathogenic mutations in founder mice, despite the fact
that they have low levels of the mutation. In fact, the mutations
are identified before the onset of any obvious disease pheno-
types and even before the mutations are detectable by standard
Sanger sequencing of tissue samples. Although the current
study used only COX staining to identify candidate mutations,
immunohistochemical staining of colonic crypts with anti-
NDUFB8 antibodies in concert with the COX/SDH staining could
allow the detection of mice with isolated CI deficiencies in future
screens. In contrast, an alternate strategy based on large-scale
phenotyping of mouse lines to detect heart, skeletal muscle, or
CNS dysfunction is very difficult and labor intensive, because
Figure 4. Abnormal Physiology Caused by Mitochondrial Dysfunction in the tRNAALA C5024T Mice
(A) Male mice carrying the C5024T mutation are smaller than age-matched wild-type animals when comparing body mass, lean mass, and fat content. n = 10–14
for each genotype and gender. Two independent cohorts were analyzed. *p < 0.05; **p < 0.01 (Dunn’s multiple comparison test).
(B) Mice with high relative levels of the C5024T mutation show elevated heart mass, indicative of cardiomyopathy. *p < 0.05 (Mann-Whitney U test).
(C) The presence of COX-negative smoothmuscle fibers in the colonic smooth muscle of mice with high levels of the C5024Tmutation after1 year of age. Black
bar represents 50 mm.
(D) Relative levels of the C5024T mutation from laser-capture dissected COX-positive and COX-negative smooth muscle fibers, showing tight co-segregation of
high levels of the mutation and COX-negative phenotype. n = 15–22 experiments per group. ****p < 0.0001 (Mann-Whitney U test).
For box-and-whisker plots, bars represent data range, + represents mean, line represents median, and box shows 25th–75th percentile of the data. See also
Figure S4.
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Figure 5. Selective Loss of the C5024T Mutation from Blood and the
Colonic Epithelium of Aged Mice
(A) Relative levels of the C5024T mutation measured from laser-capture
dissected colonic smooth muscle versus colonic epithelium from the same
mouse reveals a specific loss of the mutation in the colonic epithelium. n = 8.
**p < 0.01 (Wilcoxon matched-pairs signed rank test).
(B) Relative levels of the C5024T mutation from blood cells. Animals with high
levels of the mutation (>60% in other tissues) show decreased mutation levels
in blood at 50 weeks of age. **p < 0.01 (Mann-Whitney U test).
For box-and-whisker plots, bars represent data range, + represents mean, line
represents median, and box shows 25th–75th percentile of the data. See also
Figure S5.pathogenic mtDNA mutations are typically heteroplasmic and
cause pleiotropic symptoms that may vary with age (Larsson
and Clayton, 1995). Furthermore, a purely sequence-driven
approach to identify pathogenic mtDNA mutations is also prob-
lematic, because accurate prediction of which mutations will be
pathogenic in the mouse is quite challenging with only human
clinical data as a guide. The approach we present here also
has the advantage that it does not involve labor-intensivemanip-
ulation of ESCs or mouse embryos but instead is technically
simple and based on breeding mutant mice. Furthermore, only
pathogenic mutations that have already been maternally trans-
mitted in the germline are present in the founder mice. This2986 Cell Reports 16, 2980–2990, September 13, 2016verymuch increases the likelihood that the identifiedmtDNAmu-
tations are tolerated in the germline and can be stably trans-
mitted in the maternal lines derived from the founder mice. It
should be noted that there aremany examples where pathogenic
mtDNAmutations found in cell lines or somatic tissues will not be
inherited once introduced into mice (Fan et al., 2008; Levy et al.,
1999), because they are subject to strong purifying selection in
the maternal germline (Stewart and Larsson, 2014).
To show the feasibility of our approach, we report the genera-
tion of a mouse line with a pathogenic heteroplasmic C5024T
mutation in the tRNAALA gene of mtDNA, which recapitulates
important aspects of human mitochondrial disease. Importantly,
many pathogenic human mtDNA mutations are heteroplasmic
and will only cause respiratory chain deficiency if present above
a certain threshold. Patients with mitochondrial diseases often
harbor wild-type genomes, and interventions to target the
mutant mtDNA should therefore be a viable strategy to restore
respiratory chain function and improve the clinical condition.
Mitochondrial targeting of a restriction enzyme provided the first
proof of concept that it is possible to selectively target one of the
genotypes in mice with heteroplasmic mtDNA mutations (Bay-
ona-Bafaluy et al., 2005). Unfortunately, because most patho-
genic mutations do not alter a single restriction site in mtDNA,
mitochondrial targeting of restriction enzymes cannot be used
as a general approach. Fortunately, there has been substantial
recent progress in developing mitochondrially targeted tran-
scription activator-like effector nucleases (TALENs) or zinc-
finger nucleases that specifically cut mutant mtDNA to shift the
ratio of mutant to wild-type mtDNA in human cell lines and oo-
cytes (Bacman et al., 2013; Gammage et al., 2014; Minczuk
et al., 2006; Reddy et al., 2015). The tRNAALA mutant mice we
describe here will be a very important tool for development of
protocols for in vivo targeting of mutant mtDNA with the aim of
restoring respiratory chain function and improving phenotypes.
Furthermore, the straightforward protocol we have developed
will allow the generation of a variety of mouse models with
different types of pathogenic mtDNA mutations, which will be
invaluable tools to sort out the puzzling enigma of genotype-
phenotype correlations in mitochondrial disease.EXPERIMENTAL PROCEDURES
Animal Husbandry
Themouse strain used in all experiments was the C57Bl/6NCrl mouse (Charles
River Laboratories, Germany strain code 027). Mice were housed in a 12-hr
light/dark cycle at 21C and fed ad libitum on a standard mouse food (ssniff
M-H Low-Phytoestrogen) or an enhanced diet when breeding or newly
weaned mice (ssniff M-Z Low-Phytoestrogen) by Ssniff Spezialdiaeten
GmbH. Detailed animal husbandry protocols are available upon request.
All animal work was performed in accordance to recommendations and
guidelines of the Federation of European Laboratory Animal Science Asso-
ciations (FELASA). All experiments were approved and permitted by the
Landesamt f€ur Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen
in accordance with German and European Union regulations.
Generation of Mice with mtDNA Mutations
The mouse colony containing the proofreading-deficient variant of the mtDNA
polymerase (PolD257A; referred to as PolgAMUT) (Trifunovic et al., 2004) is
maintained by continuous backcrossing of males heterozygous for the mutant
allele to wild-type C57Bl/6NCrl females from a pure wild-type colony within the
Figure 6. tRNAALA C5024T Leads to Deple-
tion of tRNAALA and Deficiency in Mitochon-
drial Translation
(A) Northern blot analyses of various mitochondrial
tRNA, rRNA and mRNA transcripts from heart re-
veals strong depletion of the steady-state levels of
tRNAALA, and amild increase in steady-state levels
of some other mitochondrial transcripts. Data are
pooled from three independent experiments. WT,
n = 12; C5024T, n = 19 (mean age, 65 weeks;
C5024T 44%–77%). Error bars represent SD. *p <
0.05; **p < 0.01; ****p < 0.0001 (Mann-Whitney
U test).
(B) Steady-state levels of tRNAALA in comparison
with the relative levels of mtDNA with the C5024T
mutation in heart. n = 31. *p < 0.0001 (linear
regression).
(C) In organello translation of mitochondria iso-
lated from heart reveal decreased translation
capacity in tissues harboring high levels of the
mutation and the occasional appearance of low-
molecular-weight aberrant translation products (*)
consistent with prematurely terminated or stalled
translation. As a loading control, Coomassie blue
staining of proteins after SDS-PAGE is shown.
See also Figure S6.facility to avoid the accumulation of excess mtDNA mutations (Ross et al.,
2013). To generate the lines, females heterozygous for the PolgAMUT allele
were selected from the breedings described above and crossed with wild-
type C57Bl/6NCrl males. Wild-type females from these crosses were then
selected to propagate the resulting mtDNA mutations by continuous back-
crossing with wild-type C57Bl/6NCrl males.
Tissue Preparation for Histological Analysis
Mice were sacrificed with CO2 and cervical dislocation. Heart and colon tis-
sues were removed andwashedwith PBS to remove remaining blood or feces.
Tissues that were used for histological staining were frozen in isopentane (15 s)Cell Reportsthat was previously cooled to 160C in liquid
nitrogen. Tissues used in other analyses were
snap frozen in liquid nitrogen. Sections were cut
(10 mm colon, 7 mm heart) with an OFT 5000 cryo-
stat (Bright). The sections used for histological
staining were cut on to glass colorcoat adhesion
slides (CellPath) and the sections for laser-capture
dissection (15 mm) on to polyethylenenaphthalate
(PEN) slides (Leica Microsystems). Both sections
were stored in 80C prior to further analysis.
Dual COX/SDH Enzyme Histochemistry
Sections were incubated in 50 ml COX staining
medium (100 mM cytochrome c, 4 mM diamino-
benzidine tetrahydrochloride, 20 mg/ml catalase,
and 0.2 M phosphate buffer [pH 7.0]) at 37C for
25 min for colon and for heart sections 60 min
at 37C, followed by three 5-min washes with
PBS. Next, the sections were incubated with
50 ml SDH solution (130 mM sodium succinate,
200 mM phenazinemethosulphate, 1 mM sodium
azide, 1.5 mM nitroblue tetrazolium, and 0.2 M
phosphate buffer [pH 7.0]) and incubated at 37C
for 35 min for colon and at room temperature for
30 min for heart, followed by three 5-min washes
with PBS and dehydration through graded ethanol
series (70%, 95%, and 23 100%), clearing in His-toclear (National Diagnostics), and mounting in DPX. The sections for laser-
capture dissection (15 mm) that were on PEN slides were similarly exposed
to COX/SDH staining, dehydrated though graded ethanol series, and air-dried
for 90 min.
mtDNA Sequence Analysis
Detailed protocols describing DNA sequencing are published elsewhere
(Baines et al., 2014; Ross et al., 2013; Stewart et al., 2008). Briefly, 30 overlap-
ping M13-tagged primer pairs were used to amplify the mtDNA. Sequencing
reactions were carried out using the M13 primer tags with Big Dye 3.1-based
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kit. Sequences were resolved on an ABI 3730 DNA Analyzer, using 50-cm
capillary arrays and long sequencing run protocols. mtDNA sequences were
assembled using SeqScape Version 2.7. Mixed-base calls used a >20%
threshold to detect heteroplasmic mtDNA mutations, which were manually
confirmed for each mutation call. Alignment issues due to the linear represen-
tation of the circular mtDNA sequencer were overcome by duplication of the
first 212 bp of the mtDNA sequence on the reference genome’s 30 end.
Quantification of C5024T Mutation Load
Two methods were used during the course of this study to quantify the relative
levels of the mutant and wild-type mtDNAs. The first method involved a modi-
fied RFLP analysis (similar to Freyer et al., 2012). The second method involved
Allelic Quantification analysis using a PyroMark Q24 pyrosequencer (QIAGEN).
Details of the assays can be found in Supplemental Experimental Procedures.
Laser-Capture Microdissection
Laser-capture-microdissected tissues were cut to 15 mm thickness, mounted
on PEN slides (Leica Microsystems), and air-dried at room temperature for
1 hr. Slideswere stored in sealed slidemailers at80Cuntil use. Microdissec-
tion was carried out on a Leica Microsystems LMD7000 laser microdissection
microscope, sorting a single colonic crypt section or five smoothmuscle fibers
into single tubes for further analysis. Captured colonic crypts or muscle fiber
sections were settled to the bottom of the tube by centrifugation at 7,000 rcf
for 10 min. DNA was extracted in 10 ml lysis buffer (50 mM Tris-HCl [pH 8.5],
1% Tween-20, and 20 mg/ml proteinase K) for at least 2 hr and 55C, with a
heat-inactivation step at 95C for 10 min (Taylor et al., 2003). The extraction
was used directly in PCR reactions for mutation level quantification or diluted
in 30 ml water for PCR and sequencing.
Complex I Immunohistochemisty
Colons were fixed in 4% paraformaldehyde (PFA) overnight at room tempera-
ture. The formalin was then removed and the intestines washed in 70%ethanol
before standard processing for paraffin embedding. 4-mm sections were cut
and incubated at 37C overnight to ensure adherence to the slides. Sections
were de-paraffinized in two changes of Histoclear and rehydrated in a graded
EtOH series. Antigen retrieval was carried out by pressure cooking in 1 mM
EDTA (pH 8.0) for 20 min. Endogenous peroxidase activity was blocked by
the addition of 0.3% H2O2 to the 95% EtOH during the rehydration step. Sec-
tions were then incubated in 10% normal goat serum for 1 hr at room temper-
ature. Endogenous biotin was blocked using an avidin/biotin blocking kit
(Vector Laboratories). Sections were then incubated overnight at 4C inmouse
anti-NDUFB8 (Abcam) diluted 1:100 in 10% normal goat serum in Tris-buff-
ered saline. Following washing in Tris-buffered saline plus Tween 20 buffer,
sections were incubated goat anti-IgG1-biotin (Jackson ImmunoResearch
Laboratories) for 2 hr at 4C, followed by incubationwith the VECTASTAIN Elite
ABC (Vector Laboratories) as instructed by the manufacturer. NDUFB8
expression was assessed in four sections from three mice. Sections were
taken at 100-mm intervals.
Test of Neutral Segregation in the Female Germline
The segregation of the allele was tested against a neutral model using the
Kimura distribution (Wonnapinij et al., 2008). The Kimura003.c code was
downloaded, and the initial population mutation proportion in the mothers,
sample size, and variance were modified in the code before compiling for
each run. Large sample numbers are required for robust analysis, so multiple
females with ±4% of the C5024T mutation and their offspring were grouped
together for each analysis. The weighted mean of the C5024T mutation levels
in the 3-week-old tail or earclip biopsy specimens from the mothers was used
to define p. Var was calculated from the population of pup 3-week-old tail or
earclip biopsy measurements. The result of the statistical test for conforming
to the neutral distribution was retrieved from the monte_carlo1000.txt file
output from each analysis.
Body Composition Measurements
Body fat and lean content were measured in vivo by nuclear magnetic reso-
nance using a minispec LF50H (Bruker) at the Phenotyping Core Facility of
MPI for Biology of Aging.2988 Cell Reports 16, 2980–2990, September 13, 2016RNA Isolation and Northern Blot Analysis
Total RNA was isolated from snap frozen heart tissues with TRIzol (Ambion)
following themanufacturer’s standard protocol. The extracted RNAwas quan-
tified with the Nanodrop and resolved on formaldehyde-agarose gel followed
by a transfer onto Hybond-N membrane (GE Healthcare). Transcripts of inter-
est were detected with non-radioactive method essentially as previously
described (Davies et al., 2012). Briefly, the membrane was probed with
mouse-specific biotin-labeled oligonucleotides by overnight incubation in hy-
bridization buffer (53 saline sodium citrate [SSC], 20 mM Na2HPO4, 7% SDS,
0.53 RNA secure [Ambion], and 100 mg/ml heparin) at 50C followed by
washing and signal detection with IRDye 800CW dye-labeled streptavidin
(dilution 1:5000 in TBS, 0.05% tween-20) in a LI-COR Biosciences imaging
system.
Blue Native PAGE Electrophoresis
Isolation of mitochondria from mouse hearts was performed by differential
centrifugation (Mourier et al., 2014). 100 mg mitochondria was lysed with
50 ml solubilization buffer (1% [w/v] digitonin [Calbiochem], 20 mM Tris-HCl
[pH 7.4], 0,1 mM EDTA, 50 mM NaCl, and 10% [v/v] glycerol), and blue native
PAGE (BN-PAGE) was performed as previously described (Mourier et al.,
2014).
Western Blot Analysis
Proteins were separated by BN-PAGE and transferred to polyvinilidene difluor-
ide (PVDF) membrane by semi-dry transfer. Polyclonal NDUFV2 (1:1,000,
Sigma) was used for detection of Complex I and chemiluminescence detection
was performed by using Amersham ECL Prime western blotting detection re-
agent. To assure equal loading, BN-PAGE gels were stained with Coomassie
solution (Phast Gel Blue R-350, GE Healthcare).
In Gel Activity Assay
To assess the activity of CI, BN-PAGE gels were incubated in 2 mM Tris-HCl
(pH 7.4), 0.1 mg/ml NADH (Roche), and 2.5 mg/ml iodonitrozolium (Sigma)
for 30 min at room temperature. The reaction was stopped by transferring
the gels to 2 mM Tris-HCl (pH 7.4).
In Organello Translation
Mitochondria were extracted from freshly isolated hearts by differential
centrifugation. The purified mitochondria were incubated at 37C in trans-
lation buffer (100 mM mannitol, 10 mM sodium succinate, 80 mM KCl,
5 mM MgCl2, 1 mM KH2PO4, 25 mM HEPES, 200 mM ATP, 5 mM GTP,
200 mM creatine phosphate, 6 mM creatine kinase, 100 mg/ml emetine,
and 200 mg/ml cycloheximide with 6 mg/ml of every amino acid except
methionine) and 115 mCi/ml 35S-labeled methionine for 60 min. Next,
the mitochondria were washed in translation buffer and resuspended into
23 Laemmli buffer (125 mM Tris [pH 6.8], 4% SDS, 20% glycerol, 1.4 M
2-mercapto-ethanol, and 0.025% bromophenol blue.) The mitochondrial
proteins were resolved on a 17% SDS-PAGE gel and analyzed by autora-
diography. Equal loading of the mitochondria was controlled by Coomassie
staining.
DNA Extraction from Coagulated Blood
Following cervical dislocation, total blood was removed from the thoracic
cavity of the mouse and allowed to coagulate at room temperature for
2 hr. Serum was then separated from the blood with 2,000 3 g centrifuga-
tion for 20 min at room temperature. After storage at 80C, DNA was
extracted from the coagulated blood clot with Nucleospin 96 well blood
quick pure kit (MN) following the manufacturer’s recommendations.
The extracted DNA was used to detect C5024T mutation levels with
pyrosequencing.
Statistical Analysis
All statistical analyses were performed and graphs were drawn with
GraphPad Prism v6 software. a = 0.05 was used for all tests, with multiple-
testing corrections where appropriate. Typically, non-parametric tests were
used for the data analyzed. Exact tests used are referred to in the figure
legends.
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